{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:05Z","timestamp":1791906425249,"version":"4.3.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"DOI":"10.1007\/s40257-026-01075-6","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:22:09Z","timestamp":1791858129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ritlecitinib: A Review in Severe Alopecia Areata"],"prefix":"10.1007","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002586","author":"N Khaliq","year":"2024","unstructured":"Khaliq N, Riaz R, Khan M, et al. Ritlecitinib: unveiling hair regrowth for alopecia areata. Ann Med Surg. 2024. https:\/\/doi.org\/10.1097\/MS9.0000000000002586.","journal-title":"Ann Med Surg."},{"issue":"5","key":"1075_CR2","doi-asserted-by":"publisher","first-page":"e70182","DOI":"10.1002\/mco2.70182","volume":"6","author":"T Ma","year":"2025","unstructured":"Ma T, Zhang T, Miao F, et al. Alopecia areata: pathogenesis, diagnosis, and therapies. MedComm (2020). 2025;6(5):e70182.","journal-title":"MedComm (2020)"},{"issue":"10","key":"1075_CR3","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s13555-025-01517-9","volume":"15","author":"K Sanchez","year":"2025","unstructured":"Sanchez K, Englander H, Salloum L, et al. Evaluating current and emergent JAK inhibitors for alopecia areata: a narrative review. Dermatol Ther. 2025;15(10):2749\u201364.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1075_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.36849\/JDD.9292","volume":"25","author":"D DiRuggiero","year":"2026","unstructured":"DiRuggiero D, Kucera K. Efficacy, safety, and real-world aspects of Janus kinase inhibitors to treat patients with alopecia areata. J Drugs Dermatol. 2026;25(3):204\u201310.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1075_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","volume":"192","author":"MJ Harries","year":"2024","unstructured":"Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2024;192(2):190\u2013205.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1075_CR6","doi-asserted-by":"publisher","first-page":"e1155","DOI":"10.1111\/ddg.70130","volume":"24","author":"U Blume-Peytavi","year":"2026","unstructured":"Blume-Peytavi U, Constantinou A, Tomova-Simitchieva T, et al. S3 guideline diagnostics and therapy in alopecia areata\u2014part 2: therapy, psychosocial and cosmetic support. J Dtsch Dermatol Ges. 2026;24(8):e1155\u201377.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1075_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.2336","author":"S Gregoire","year":"2026","unstructured":"Gregoire S, Dewey E, Biba U, et al. Delphi consensus statement on treatment of severe alopecia areata in US adults. JAMA Dermatol. 2026. https:\/\/doi.org\/10.1001\/jamadermatol.2026.2336.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1075_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1075_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"23","key":"1075_CR10","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/1381612043383638","volume":"10","author":"E Pfitzner","year":"2004","unstructured":"Pfitzner E, Kliem S, Baus D, et al. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des. 2004;10(23):2839\u201350.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"1075_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342.","journal-title":"ACS Chem Biol"},{"issue":"12","key":"1075_CR12","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"J-B Telliez","year":"2016","unstructured":"Telliez J-B, Dowty ME, Wang L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442\u201351.","journal-title":"ACS Chem Biol"},{"key":"1075_CR13","unstructured":"Pfizer Inc. LITFULOTM (ritlecitinib) capsules, for oral use. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215830s000lbl.pdf. Accessed 16 Sept 2026."},{"key":"1075_CR14","unstructured":"European Medicines Agency. Litfulo 50 mg hard capsules: EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/litfulo-epar-product-information_en.pdf. Accessed 16 Sept 2026."},{"issue":"14","key":"1075_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA. Ritlecitinib: first approval. Drugs. 2023;83(14):1315\u201321.","journal-title":"Drugs"},{"issue":"9","key":"1075_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40267-024-01086-5","volume":"40","author":"M Shirley","year":"2024","unstructured":"Shirley M. Ritlecitinib in severe alopecia areata: a profile of its use. Drugs Ther Perspect. 2024;40(9):341\u20139.","journal-title":"Drugs Ther Perspect"},{"issue":"10387","key":"1075_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"key":"1075_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01029-y","author":"M Senna","year":"2026","unstructured":"Senna M, Soung J, Figueras I, et al. Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO phase 2b\/3 and ALLEGRO-LT phase 3 clinical studies. Am J Clin Dermatol. 2026. 2026;27:1091-1105.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1075_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2024.09.064","volume":"92","author":"M Piliang","year":"2025","unstructured":"Piliang M, Lynde C, King B, et al. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b\/3 trial. J Am Acad Dermatol. 2025;92(2):276\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1075_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/1346-8138.17539","volume":"52","author":"X Zhang","year":"2025","unstructured":"Zhang X, Ye Y, Sun W, et al. Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: a subgroup analysis of the ALLEGRO phase 2b\/3 trial. J Dermatol. 2025;52(4):603\u201314.","journal-title":"J Dermatol"},{"issue":"11","key":"1075_CR21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/1346-8138.17442","volume":"51","author":"N Mesinkovska","year":"2024","unstructured":"Mesinkovska N, King B, Zhang X, et al. Efficacy and safety of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. J Dermatol. 2024;51(11):1414\u201324.","journal-title":"J Dermatol"},{"issue":"10","key":"1075_CR22","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s13555-024-01260-7","volume":"14","author":"J Fu","year":"2024","unstructured":"Fu J, Egeberg A, Holmes S, et al. Impact of previous alopecia areata treatment on efficacy responses up to week 48 following ritlecitinib treatment: a post hoc analysis. Dermatol Ther. 2024;14(10):2759\u201369.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1075_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/pde.15378","volume":"40","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023;40(6):1003\u20139.","journal-title":"Pediatr Dermatol"},{"key":"1075_CR24","unstructured":"U.S. Food & Drug Administration. Litfulo (ritlecitinib) capsule: multi-disciplinary review. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215830Orig1s000MultidisciplineR.pdf. Accessed 16 Sept 2026."},{"issue":"5\u20136","key":"1075_CR25","first-page":"767","volume":"240","author":"R Sinclair","year":"2024","unstructured":"Sinclair R, Law EH, Zhang XQ, et al. Patient-reported satisfaction with hair regrowth in a study of ritlecitinib in alopecia areata: results from ALLEGRO-2b\/3. Dermatol. 2024;240(5\u20136):767\u201377.","journal-title":"Dermatol"},{"issue":"10","key":"1075_CR26","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s13555-023-00997-x","volume":"14","author":"D Thaci","year":"2023","unstructured":"Thaci D, Tziotzios C, Ito T, et al. Hair loss profiles and ritlecitinib efficacy in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b\/3 study. Dermatol Ther. 2023;14(10):2621\u201334.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1075_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/ijd.70035","volume":"65","author":"EH Law","year":"2025","unstructured":"Law EH, Sherif B, Mostaghimi A, et al. Improvement in patient-reported emotional symptoms and activity limitations due to hair loss in patients with alopecia areata treated with ritlecitinib: additional analyses from ALLEGRO-2b\/3. Int J Dermatol. 2025;65(3):526\u201334.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1075_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40257-024-00899-4","volume":"26","author":"R Sinclair","year":"2025","unstructured":"Sinclair R, Mesinkovska N, Mitra D, et al. Patient-reported hair loss and its impacts as measured by the alopecia areata patient priority outcomes instrument in patients treated with ritlecitinib: the ALLEGRO phase 2b\/3 randomized clinical trial. Am J Clin Dermatol. 2025;26(1):109\u201319.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1075_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jdv.20547","volume":"39","author":"B King","year":"2025","unstructured":"King B, Mirmirani P, Lo Sicco K, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3 Suppl","key":"1075_CR30","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.jid.2025.02.128","volume":"145","author":"U Blume-Peytavi","year":"2025","unstructured":"Blume-Peytavi U, Craiglow B, Netravali IA, et al. Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study [abstract no. 125]. J Investig Dermatol. 2025;145(3 Suppl):e30.","journal-title":"J Investig Dermatol"},{"key":"1075_CR31","unstructured":"Piliang M, Soung J, King B, et al. Efficacy of ritlecitinib up to month 24 in patients with alopecia totalis (AT) and alopecia universalis (AU) from the ALLEGRO phase 2b\/3 and long-term phase 3 clinical studies [abstract]. In: American Academy of Dermatology (AAD). 2024."},{"issue":"4","key":"1075_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/1346-8138.70154","volume":"53","author":"R Ueki","year":"2026","unstructured":"Ueki R, Mizuashi M, Harada K, et al. Efficacy and safety of ritlecitinib in the Asian subpopulation of the ALLEGRO-2b\/3 and ALLEGRO-LT clinical studies for alopecia areata. J Dermatol. 2026;53(4):578\u201386.","journal-title":"J Dermatol"},{"issue":"1 Suppl","key":"1075_CR33","doi-asserted-by":"publisher","first-page":"AB288","DOI":"10.1016\/j.jaad.2026.04.1162","volume":"95","author":"L Rudnicka","year":"2026","unstructured":"Rudnicka L, Mazereeuw-Hautier J, Netravali IA, et al. Long-term efficacy, complete scalp hair regrowth and normal body hair\/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials [abstract no. 75893]. J Am Acad Dermatol. 2026;95(1 Suppl):AB288.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1075_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/ced\/llaf509","volume":"51","author":"L Foggia","year":"2025","unstructured":"Foggia L, Nappa P, Ocampo-Garza SS, et al. Comparative clinical, trichoscopic, and safety outcomes of baricitinib, ritlecitinib, and upadacitinib in alopecia areata: a real-world experience. Clin Exp Dermatol. 2025;51(3):491\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1075_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40257-026-01022-5","volume":"27","author":"M Starace","year":"2026","unstructured":"Starace M, Rapparini L, Pampaloni F, et al. Ritlecitinib for severe alopecia areata: a 24-week, multicentre, real-world study. Am J Clin Dermatol. 2026;27(3):621\u201330.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1075_CR36","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/ced\/llaf312","volume":"50","author":"L Valtellini","year":"2025","unstructured":"Valtellini L, Avallone G, Murgia G, et al. Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study. Clin Exp Dermatol. 2025;50(11):2297\u2013300.","journal-title":"Clin Exp Dermatol"},{"key":"1075_CR37","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42990","author":"SC Van Helmond","year":"2025","unstructured":"Van Helmond SC, Willaert M, Nguyen VH, et al. Real-world effectiveness and safety of Janus kinase inhibitors in alopecia areata: a retrospective cohort study of 72 patients. Acta Derm Venereol. 2025. https:\/\/doi.org\/10.2340\/actadv.v105.42990.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1075_CR38","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/ijd.70330","volume":"65","author":"P Franzese","year":"2026","unstructured":"Franzese P, Balato A, Di Brizzi EV, et al. Ritlecitinib efficacy in adolescents with alopecia areata: a real-world experience. Int J Dermatol. 2026;65(9):1932\u20134.","journal-title":"Int J Dermatol"},{"key":"1075_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.07.009","author":"M Starace","year":"2026","unstructured":"Starace M, Cedirian S, Pampaloni F, et al. Real-world effectiveness and safety of ritlecitinib in adolescents with severe alopecia areata: a 36-week single-center study. J Am Acad Dermatol. 2026. https:\/\/doi.org\/10.1016\/j.jaad.2026.07.009.","journal-title":"J Am Acad Dermatol"},{"key":"1075_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/dth\/1771776","author":"N Perrotta","year":"2026","unstructured":"Perrotta N, Fiorito LA, Vescovo R, et al. Trichoscopic markers and clinical response patterns with ritlecitinib in severe alopecia areata: 24-week outcomes from a prospective real-world cohort. Dermatol Ther. 2026. https:\/\/doi.org\/10.1155\/dth\/1771776.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1075_CR41","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ced\/llag067","volume":"51","author":"N Sebastian","year":"2026","unstructured":"Sebastian N, Abraheem A, Chandidzura A, et al. Ritlecitinib for the treatment of severe alopecia areata: real-world experience from a UK tertiary centre. Clin Exp Dermatol. 2026;51(7):1301\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"1075_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llag272","author":"D Li","year":"2026","unstructured":"Li D, Bhanot R, Sethi Nayyar S, et al. A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: early real world experience in a British cohort. Clin Exp Dermatol. 2026. https:\/\/doi.org\/10.1093\/ced\/llag272.","journal-title":"Clin Exp Dermatol"},{"issue":"1 Suppl","key":"1075_CR43","doi-asserted-by":"publisher","first-page":"AB373","DOI":"10.1016\/j.jaad.2026.04.1490","volume":"95","author":"S Nayyar","year":"2026","unstructured":"Nayyar S, Li D, Bhanot R, et al. Real-world efficacy data of oral ritlecitinib in severe alopecia areata: a multicentre UK experience [abstract no. 74280 ]. J Am Acad Dermatol. 2026;95(1 Suppl):AB373.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1075_CR44","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s13555-026-01773-3","volume":"16","author":"SK Kurosky","year":"2026","unstructured":"Kurosky SK, Cha-Silva AS, Austin J, et al. Real-world ritlecitinib treatment of severe alopecia areata in the United States: patient characteristics and physician satisfaction according to a secondary database analysis. Dermatol Ther. 2026;16(7):3513\u201328.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1075_CR45","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.jaad.2026.01.055","volume":"94","author":"A Martin","year":"2026","unstructured":"Martin A, Chen L-C, Kreytak C, et al. Switching between Janus kinase inhibitors for treatment of alopecia areata: a multicenter retrospective review. J Am Acad Dermatol. 2026;94(6):1662\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1075_CR46","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1093\/ced\/llaf194","volume":"50","author":"R Dai","year":"2025","unstructured":"Dai R, Duan L, Li S, et al. Ritlecitinib in clinical practice: a real-world study of efficacy, safety and prior Janus kinase inhibitor impact in alopecia areata. Clin Exp Dermatol. 2025;50(9):1866\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1075_CR47","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jaad.2025.07.008","volume":"93","author":"J Huang","year":"2025","unstructured":"Huang J, Jian J, Li M, et al. Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: potential rapid response predictors. J Am Acad Dermatol. 2025;93(5):1236\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"1075_CR48","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v106.adv-2025-0060","author":"R Ji","year":"2026","unstructured":"Ji R, Zhang M, Tian T, et al. Comparative efficacy of JAK inhibitors in acute vs nonacute alopecia areata: a retrospective cohort study. Acta Derm Venereol. 2026. https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0060.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"1075_CR49","doi-asserted-by":"publisher","first-page":"e996","DOI":"10.1111\/jdv.20664","volume":"39","author":"Y Sheng","year":"2025","unstructured":"Sheng Y, Wang Q, Tao K, et al. Real-world efficacy and safety of ritlecitinib in alopecia areata: a single-centre experience. J Eur Acad Dermatol Venereol. 2025;39(12):e996\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1075_CR50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaad.2025.06.041","volume":"93","author":"W Zhang","year":"2025","unstructured":"Zhang W, Li X, Zhang Y, et al. Ritlecitinib in alopecia areata: a multicenter retrospective real-world analysis. J Am Acad Dermatol. 2025;93(4):1136\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1075_CR51","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jaad.2025.10.008","volume":"94","author":"M Xu","year":"2026","unstructured":"Xu M, Leong H, Zhu Y, et al. Evaluating the early efficacy and safety of ritlecitinib in moderate alopecia areata: a real-world, single-center study. J Am Acad Dermatol. 2026;94(2):618\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1075_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/12034754251387712","volume":"30","author":"J Huang","year":"2026","unstructured":"Huang J, Chisanga M, Li M, et al. Real-world effectiveness of JAK inhibitors for alopecia totalis and alopecia universalis: a single-center experience. J Cutan Med Surg. 2026;30(2):143\u20139.","journal-title":"J Cutan Med Surg"},{"issue":"1 Suppl","key":"1075_CR53","doi-asserted-by":"publisher","first-page":"AB207","DOI":"10.1016\/j.jaad.2026.04.844","volume":"95","author":"W Wu","year":"2026","unstructured":"Wu W, Xu M, Leong H, et al. Evaluating the early efficacy and safety of ritlecitinib in moderate alopecia areata: a real-world, single-center study [abstract no. 73494]. J Am Acad Dermatol. 2026;95(1 Suppl):AB207.","journal-title":"J Am Acad Dermatol"},{"key":"1075_CR54","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v106.adv-2026-0453","author":"X Ke","year":"2026","unstructured":"Ke X, Gao Y, Huang J, et al. Treatment response to JAK inhibitors in long-standing alopecia areata (\u22658 years): a real-world observational study. Acta Derm Venereol. 2026. https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0453.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1075_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/12034754261429965","volume":"30","author":"J Huang","year":"2026","unstructured":"Huang J, Zhang Z, Jian J, et al. Real-world efficacy of ritlecitinib in adolescent patients with alopecia areata: a 36 week monocentric real-life observational study. J Cutan Med Surg. 2026;30(4):369\u201373.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1075_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/1346-8138.70123","volume":"53","author":"T Okazaki","year":"2026","unstructured":"Okazaki T, Takahashi T, Wada-Irimada M, et al. Ritlecitinib in alopecia areata: a 24-week real-world experience contrasting JAK inhibitor-naive and JAK inhibitor-experienced patients. J Dermatol. 2026;53(3):470\u20137.","journal-title":"J Dermatol"},{"key":"1075_CR57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25:299\u2013314.","journal-title":"Am J Clin Dermatol"},{"key":"1075_CR58","doi-asserted-by":"crossref","unstructured":"Senna MM, Hanna S, Ueki R, et al. Updated integrated safety analysis of ritlecitinib up to ~5 years in patients with alopecia areata (AA) from the ALLEGRO clinical trial program [abstract no. 4622]. In: European Academy of Dermatology and Venereology (EADV) congress. 2025.","DOI":"10.25251\/0j9fht97"},{"issue":"3 Suppl","key":"1075_CR59","doi-asserted-by":"publisher","first-page":"AB55","DOI":"10.1016\/j.jaad.2024.07.228","volume":"91","author":"K Lo Sicco","year":"2024","unstructured":"Lo Sicco K, Soung J, Strober B, et al. Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA [abstract no. 52875]. J Am Acad Dermatol. 2024;91(3 Suppl):AB55.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1075_CR60","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40257-023-00799-z","volume":"24","author":"S Fung","year":"2023","unstructured":"Fung S, Shirley M. Baricitinib: a review in severe alopecia areata. Am J Clin Dermatol. 2023;24(4):661\u20138.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1075_CR61","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40261-026-01568-6","volume":"46","author":"S Fung","year":"2026","unstructured":"Fung S. Deuruxolitinib: new approval. Clin Drug Investig. 2026;46(8):925\u201330.","journal-title":"Clin Drug Investig"},{"key":"1075_CR62","unstructured":"National Institute for Health and Care Excellence. Ritlecitinib for treating severe alopecia areata in people 12 years and over. 2024. http:\/\/www.nice.org.uk. Accessed 16 Sept 2026."},{"issue":"6","key":"1075_CR63","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/jdv.20686","volume":"39","author":"J Seneschal","year":"2025","unstructured":"Seneschal J. Alopecia areata and ritlecitinib: unravelling response trajectories. J Eur Acad Dermatol Venereol. 2025;39(6):1074\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1 Suppl","key":"1075_CR64","doi-asserted-by":"publisher","first-page":"AB375","DOI":"10.1016\/j.jaad.2026.04.1498","volume":"95","author":"G Schaefer","year":"2026","unstructured":"Schaefer G, Kindred C, Ito T, et al. Real-world study in progress: characterization and clinical outcomes of alopecia areata patients treated with ritlecitinib in a real-world cohort (PRESTO) [abstract no. 73744 ]. J Am Acad Dermatol. 2026;95(1 Suppl):AB375.","journal-title":"J Am Acad Dermatol"},{"key":"1075_CR65","unstructured":"US National Institutes of Health. http:\/\/www.clinicaltrials.gov. 2025. Accessed 16 Sept 2026."},{"issue":"2","key":"1075_CR66","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","volume":"87","author":"E Peeva","year":"2022","unstructured":"Peeva E, Guttman-Yassky E, Banerjee A, et al. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol. 2022;87(2):390\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1075_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2025.09.007","volume":"29","author":"J Mauer","year":"2025","unstructured":"Mauer J, Whichello C, Hauber B, et al. A patient preference-weighted quantitative benefit-risk analysis of ritlecitinib for alopecia areata to inform medical decision making. Value Health. 2025;29(2):277\u201384.","journal-title":"Value Health"},{"issue":"12","key":"1075_CR68","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1007\/s13555-025-01543-7","volume":"15","author":"B King","year":"2025","unstructured":"King B, McMichael A, Sinclair R, et al. Rationale and design of a novel, phase 3, external and synthetic placebo-controlled clinical trial of ritlecitinib 50 mg and 100 mg for alopecia areata. Dermatol Ther. 2025;15(12):3793\u2013803.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1075_CR69","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/jdv.20372","volume":"39","author":"D Aceituno","year":"2025","unstructured":"Aceituno D, Fawsitt CG, Power GM, et al. Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. J Eur Acad Dermatol Venereol. 2025;39(6):1134\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"16","key":"1075_CR70","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019;79(16):1819\u201328.","journal-title":"Drugs"},{"issue":"4","key":"1075_CR71","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/pde.15895","volume":"42","author":"ME Gonzalez","year":"2025","unstructured":"Gonzalez ME, Browning J, Smith S, et al. A phase 1, open-label study of the pharmacokinetics of ritlecitinib in children aged 6-12\u2009years with alopecia areata. Pediatr Dermatol. 2025;42(4):742\u20136.","journal-title":"Pediatr Dermatol"},{"key":"1075_CR72","doi-asserted-by":"crossref","unstructured":"Cha-Silva AS, Zhang AH, Graham CN. A cost-per-responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe alopecia areata [abstract no. EE326 plus poster]. In: ISPOR 2025. 2025.","DOI":"10.1016\/j.jval.2025.04.1925"},{"issue":"4","key":"1075_CR73","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/1346-8138.70212","volume":"53","author":"A Yuasa","year":"2026","unstructured":"Yuasa A, Kamei K, Saito S, et al. Cost-effectiveness analysis of ritlecitinib compared with no treatment in patients with severe alopecia areata in Japan. J Dermatol. 2026;53(4):619\u201331.","journal-title":"J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01075-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:07:09Z","timestamp":1791904029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01075-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":73,"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01075-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"21 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The preparation of this review was not supported by any external funding.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","label":"Authorship and conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}